Using the AAV-A53T α-synuclein rat model, the present study was conducted to investigate the extent to which GM1 ganglioside administration could protect against α-synuclein toxicity and development of PD-relevant pathological changes and behavioral deficits. Here, SNCA is linked to Parkinson disease.